Related Experiment Video
Updated: Jun 17, 2026
12:09
Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
[Recombinant antibodies against bioweapons]
Philippe Thullier1, Thibaut Pelat, Dominique Vidal
1Groupe de biotechnologie des anticorps, département des agents transmissibles, Centre de recherche du Service de santé des armées, 38702 La Tronche Cedex, France. pthullier@yahoo.com
Medecine Sciences : M/S
|December 29, 2009
Summary
Bioweapons pose a significant threat, but recombinant antibodies offer a solution. Researchers developed novel antibodies using non-human primate libraries to neutralize deadly bioweapons like anthrax and smallpox.
Area of Science:
- Biotechnology
- Immunology
- Infectious Diseases
Context:
- Bioweapons (BW) present a risk of re-emerging deadly diseases like plague and smallpox.
- Recombinant antibodies are well-tolerated, suitable for prophylaxis and treatment, and can neutralize BW agents.
Purpose:
- To develop novel recombinant antibodies for neutralizing bioweapons.
- To utilize phage-displayed immune libraries from non-human primates (M. fascicularis) for antibody discovery.
Summary:
- Researchers successfully generated recombinant antibodies capable of neutralizing dangerous bioweapons.
- The approach involved creating phage-displayed immune libraries from M. fascicularis, followed by antibody isolation.
- These antibodies can be further modified to enhance human compatibility (germlining).
Impact:
- Provides a promising strategy for developing medical countermeasures against bioweapon threats.
- Advances the field of antibody engineering for biodefense applications.
- Offers potential for prophylaxis and treatment against eradicated diseases re-emerging due to bioweapons.
Related Concept Videos
00:42Cross-reactivity
Overview
01:09Recombinant DNA
Overview
01:09Recombinant DNA
Overview
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:26Antibody Actions
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...